表紙
市場調査レポート

アジア太平洋地域の無侵襲的出生前遺伝学的検査(NIPT)市場の見通し

Asia Pacific NIPT Market Outlook 2018

発行 RNCOS E-Services Pvt. Ltd. 商品コード 312363
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
アジア太平洋地域の無侵襲的出生前遺伝学的検査(NIPT)市場の見通し Asia Pacific NIPT Market Outlook 2018
出版日: 2014年09月01日 ページ情報: 英文 55 Pages
概要

無侵襲的出生前遺伝学的検査(NIPT)市場は、分子診断市場で急成長を遂げています。アジア太平洋地域は、世界人口のほぼ3分の1を占め、潜在患者(ハイリスク年齢層)は約200万人、20億米ドル以上の価値があると見られています。

当レポートでは、アジア太平洋地域におけるNIPT市場について調査分析し、検査の概要、ダウン症のリスク、国別市場の潜在力・概要・規制シナリオなどについて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 イントロダクション

第4章 胎児に対するダウン症(DS)のリスクと母親の年齢との関連

第5章 アジア太平洋地域のNIPT市場の見通し

  • オーストラリア
    • 市場の潜在力
    • 市場概要
    • 規制シナリオ
  • 中国
    • 市場の潜在力
    • 市場概要
    • 規制シナリオ
  • 日本
    • 市場の潜在力
    • 市場概要
    • 規制シナリオ
  • インド
    • 市場の潜在力
    • 規制シナリオ

図表

目次

Non-Invasive Prenatal Testing (NIPT) has catapulted growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during 2013-2018. However, owing to a restrictive potential population base in USA, which is estimated at around 700,000, companies based in the region have been quick to expand beyond their geography and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For RNCOS' study, its experts have selected the APAC region since it represents a highly under penetrated market with immense potential for growth.

The APAC has almost one-third of the global population. According to RNCOS' report "Asia Pacific NIPT Market Outlook 2018", there are around 2 Million potential patients (high-risk age group) in the region, representing an over US$ 2 Billion worth potential market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for the companies. China is another major region where two local players, BGI and Berry Genomics, are estimated to have collectively conducted around 100,000 tests in 2013 alone.

With the launch of a few NIPT tests, India represents a great opportunity for the growth of NIPT. The trend of pregnancies has witnessed a fundamental change in India in terms of the age of conceiving. Previously, the age group for pregnancy was usually 25 to 30 years. Now, it has increased to 28 to 35 years and above 35 years in some cases. This, therefore, augurs well for the growth of NIPT in India over the next few years. However, the growth can be marred by a lack of awareness of such tests and relatively lower affordability, with a major chunk of births taking place in the rural India.

RNCOS, in its report, covers an exhaustive analysis of the potential population for NIPT tests in the various regions. Different scenarios have also been explored in line with the regulatory environment in the different regions. Detailed description too has been provided of the current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them, etc.

Besides, test volumes and markets till 2018 have been forecasted. These forecasts have been conducted on the basis of co-relation and judgmental analysis, which was carried out after carefully studying key factors, including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario, and various other drivers and challenges.

Overall, the report presents optimum information and a transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction

  • 3.1 MaterniT21 PLUS
  • 3.2 Verifi
  • 3.3 Panorama
  • 3.4 Harmony
  • 3.5 NIFTY
  • 3.6 Bambni

4. Association of Down's syndrome Risk to Fetus with Mother's Age

5. Asia-Pacific NIPT Market Outlook to 2018

  • 5.1 Australia
    • 5.1.1 Market Potential
    • 5.1.2 Market Overview
    • 5.1.3 Regulatory Scenario
  • 5.2 China
    • 5.2.1 Market Potential
    • 5.2.2 Market Overview
    • 5.2.3 Regulatory Scenario
  • 5.3 Japan
    • 5.3.1 Market Potential
    • 5.3.2 Market Overview
    • 5.3.3 Regulatory Scenario
  • 5.4 India
    • 5.4.1 Market Potential
    • 5.4.2 Regulatory Scenario

List of Figures:

  • Figure 5-1: Australia - Number of Births ('000), 2012-2018
  • Figure 5-2: Australia - Number of Births by Mother's Risk of Down's syndrome (%), 2013
  • Figure 5-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
  • Figure 5-4: Australia - NIPT Market (Million US$), 2013-2018
  • Figure 5-5: Australia - NIPT Market (Volume '000), 2013-2018
  • Figure 5-6: China - Number of Births (Million), 2012-2018
  • Figure 5-7: China - Number of Births by Mother's Risk of Down's syndrome (%), 2013
  • Figure 5-8: China - Potential Market in Two Different Scenarios (US$), 2013
  • Figure 5-9: China - NIPT Market (Million US$), 2013-2018
  • Figure 5-10: China - NIPT Market (Volume '000), 2013-2018
  • Figure 5-11: Japan - Number of Births ('000), 2012-2018
  • Figure 5-12: Japan - Number of Births by Mother's Risk of Down's syndrome (%), 2013
  • Figure 5-13: Japan - Potential Market in Two Different Scenarios (US$), 2013
  • Figure 5-14: Japan - NIPT Market (Million US$), 2013-2018
  • Figure 5-15: Japan - NIPT Market (Volume '00), 2013-2018
  • Figure 5-16: India - Number of Births (Million), 2012-2018
  • Figure 5-17: India - Number of Births by Mother's Risk of Down's syndrome (%), 2013
  • Figure 5-18: India - Potential Market in Two Different Scenarios (US$), 2013

List of Tables:

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: MaterniT21 PLUS Test Validation Results
  • Table 3-3: Verifi Test Validation Results
  • Table 3-4: Panorma Test Validation Results
  • Table 3-5: Harmony Test Validation Results
  • Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
  • Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
  • Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
  • Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
  • Table 4-1: Risk of Down's syndrome with Rise in Maternal Age
  • Table 5-1: Australia - Number of Births by Age of Mother (2012)
  • Table 5-2: Australia - Number of Births by Age of Mother (2013)
  • Table 5-3: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
  • Table 5-4: China - Number of Births by Age of Mother (2012)
  • Table 5-5: China - Number of Births by Age of Mother (2013)
  • Table 5-6: China NIPT Market Landscape - Players; Cost per Test
  • Table 5-7: Japan - Number of Births by Age of Mother (2012)
  • Table 5-8: Japan - Number of Births by Age of Mother (2013)
  • Table 5-9: Japan NIPT Market Landscape - Player; Cost per Test
  • Table 5-10: India - Number of Births by Age of Mother (2000)
  • Table 5-11: India - India - Number of Births by Age of Mother (2013)
Back to Top